SWTX
SWTX Real Time Price USDRecent trades of SWTX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SWTX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
SWTX Revenue by Segment or Geography
New patents grants
-
Patent Title: Non-linear dosing of mirdametinib Apr. 01, 2025
-
Patent Title: Mirdametinib treatment Mar. 25, 2025
-
Patent Title: Synthesis of nirogacestat Mar. 11, 2025
-
Patent Title: Synthesis of nirogacestat Feb. 25, 2025
-
Patent Title: Mirdametinib treatment Feb. 11, 2025
-
Patent Title: Treatments with nirogacestat Jan. 07, 2025
-
Patent Title: Treatments with nirogacestat Nov. 12, 2024
-
Patent Title: Synthesis of nirogacestat Oct. 08, 2024
-
Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof Sep. 17, 2024
-
Patent Title: Treatments with nirogacestat Jul. 16, 2024
-
Patent Title: 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead Jul. 09, 2024
-
Patent Title: Dosage forms of mirdametinib Jul. 09, 2024
-
Patent Title: Treatments with nirogacestat Jun. 18, 2024
-
Patent Title: Treatments with nirogacestat Jun. 18, 2024
-
Patent Title: Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinib Jun. 18, 2024
-
Patent Title: Treatments with nirogacestat Apr. 16, 2024
-
Patent Title: Treatments with nirogacestat Apr. 09, 2024
-
Patent Title: Treatments with nirogacestat Mar. 26, 2024
-
Patent Title: Treatments with nirogacestat Mar. 12, 2024
-
Patent Title: Treatments with nirogacestat Mar. 12, 2024
-
Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Jan. 30, 2024
-
Patent Title: Mirdametinib treatment Jan. 30, 2024
-
Patent Title: Treatments with nirogacestat Jan. 16, 2024
-
Patent Title: Chlorinated tetralin compounds and pharmaceutical compositions Dec. 19, 2023
-
Patent Title: Mirdametinib treatment Dec. 12, 2023
-
Patent Title: Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinib Nov. 21, 2023
-
Patent Title: Chlorinated tetralin compounds and pharmaceutical compositions Nov. 07, 2023
-
Patent Title: Mirdametinib treatment Nov. 07, 2023
-
Patent Title: Non-linear dosing of mirdametinib Nov. 07, 2023
-
Patent Title: Fluorinated phenylamino compounds and pharmaceutical compositions Oct. 10, 2023
-
Patent Title: Dispersible formulations of n-((r)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Feb. 07, 2023
-
Patent Title: Solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereof Aug. 30, 2022
-
Patent Title: Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof Aug. 10, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to SWTX
Recent picks made for SWTX stock on CNBC
ETFs with the largest estimated holdings in SWTX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $SWTX stock a Buy, Sell, or Hold?
- What is the price target for $SWTX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $SWTX stock?
- Who owns the most shares of $SWTX stock?
- What funds own $SWTX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SWTX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.